These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37755979)

  • 1. Safety and Effectiveness of OnabotulinumtoxinA in Patients with Laryngeal Dystonia: Final Report of a 52-Week, Multicenter Postmarketing Surveillance Study.
    Iimura S; Nose Y; Tabata K; Oda K; Yamashita Y; Takahashi N; Kawano Y
    Toxins (Basel); 2023 Sep; 15(9):. PubMed ID: 37755979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved vocal quality and decreased vocal effort after botulinum toxin treatment for laryngeal dystonia.
    Leung JS; Rosenbaum A; Holmberg J; Villarroel P; Napolitano C; Badía PI; Lagos-Villaseca A
    Auris Nasus Larynx; 2024 Feb; 51(1):106-112. PubMed ID: 37365040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IncobotulinimtoxinA (Xeomin) for the treatment of adductor laryngeal dystonia: A prospective, open-label clinical trial.
    Kohli N; Lerner M; Rashty J; Kirke D; Stewart T; Blitzer A
    Am J Otolaryngol; 2022; 43(6):103613. PubMed ID: 36055061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OnabotulinumtoxinA for adductor spasmodic dysphonia (ADSD): Functional results and the role of dosage.
    Marchese MR; D'Alatri L; Bentivoglio AR; Paludetti G
    Toxicon; 2018 Dec; 155():38-42. PubMed ID: 30315835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE).
    Jankovic J; Adler CH; Charles D; Comella C; Stacy M; Schwartz M; Manack Adams A; Brin MF
    J Neurol Sci; 2015 Feb; 349(1-2):84-93. PubMed ID: 25595221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of Life After Botulinum Toxin Injection in Patients With Adductor Spasmodic Dysphonia; a Systematic Review and Meta-analysis.
    Faham M; Ahmadi A; Silverman E; Harouni GG; Dabirmoghaddam P
    J Voice; 2021 Mar; 35(2):271-283. PubMed ID: 31477348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative laryngeal electromyography parameters may correlate with improved outcomes following botulinum toxin injection for spasmodic dysphonia.
    Dwyer CD; Leclerc AA; Nandedkar SD; Young VN; Rosen CA
    Muscle Nerve; 2021 Apr; 63(4):525-530. PubMed ID: 33382480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxin injection into the intrinsic laryngeal muscles to treat spasmodic dysphonia: A multicenter, placebo-controlled, randomized, double-blinded, parallel-group comparison/open-label clinical trial.
    Hyodo M; Nagao A; Asano K; Sakaguchi M; Mizoguchi K; Omori K; Tada Y; Hatakeyama H; Oridate N; Naito K; Iwata Y; Shinomiya H; Hara H; Sanuki T; Yumoto E
    Eur J Neurol; 2021 May; 28(5):1548-1556. PubMed ID: 33393175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors Associated with Failure of Botulinum Toxin Injection in Adductor Spasmodic Dysphonia.
    Zhao K; Guillaud M; Hu A
    Ann Otol Rhinol Laryngol; 2020 Oct; 129(10):996-1002. PubMed ID: 32468829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia.
    Morzaria S; Damrose EJ
    J Voice; 2012 May; 26(3):378-80. PubMed ID: 20951552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study.
    Ahmed F; Gaul C; García-Moncó JC; Sommer K; Martelletti P;
    J Headache Pain; 2019 Mar; 20(1):26. PubMed ID: 30845917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Botulinum toxin. A new therapeutic alternative in spastic dysphonia (laryngeal abductor dystonia)].
    Loven JO; Brøndbo K; Ganes T
    Tidsskr Nor Laegeforen; 1993 Mar; 113(7):841-3. PubMed ID: 8480289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
    Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perceptions regarding communicative participation in individuals receiving botulinum toxin injections for laryngeal dystonia.
    Yorkston K; Baylor CR; Eadie T; Kapsner-Smith M
    Int J Lang Commun Disord; 2021 Nov; 56(6):1296-1315. PubMed ID: 34453393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Laryngeal dystonia: novel forms of therapeutic administration of botulinum toxin by direct routes].
    Lopez Del Val LJ; Sebastian-Cortes JM; Bellosta-Diago E; Santos-Lasaosa S; Vinueza-Buitron PR; Lois-Ortega Y; Valles-Varea H; Lopez-Garcia E
    Rev Neurol; 2018 Jun; 66(11):368-372. PubMed ID: 29790569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum Neurotoxin Therapy in the Clinical Management of Laryngeal Dystonia.
    Yeung W; Richards AL; Novakovic D
    Toxins (Basel); 2022 Dec; 14(12):. PubMed ID: 36548741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Laryngeal Botulinum Neurotoxin Injection With Work Productivity for Patients With Spasmodic Dysphonia.
    Meyer TK; Spiekerman C; Kaye R; Blitzer A; Kamizi RS; Jiang L; Weaver EM
    JAMA Otolaryngol Head Neck Surg; 2021 Sep; 147(9):804-810. PubMed ID: 34351425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment efficacy of electromyography versus fiberscopy-guided botulinum toxin injection in adductor spasmodic dysphonia patients: a prospective comparative study.
    Kim JW; Park JH; Park KN; Lee SW
    ScientificWorldJournal; 2014; 2014():327928. PubMed ID: 25383369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of cervical dystonia with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice.
    Jochim A; Meindl T; Mantel T; Zwirner S; Zech M; Castrop F; Haslinger B
    J Neurol; 2019 Aug; 266(8):1879-1886. PubMed ID: 31049731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient Experience Contributing to Outcomes of Laryngeal Botulinum Toxin Injection.
    Rutt A; Kennelly KD; Martinez-Paredes JF
    J Voice; 2022 Mar; 36(2):272-276. PubMed ID: 32553551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.